Document Details
|
Document Type |
: |
Thesis |
|
Document Title |
: |
HEPATOTOXICITY IN CANCER PATIENTS RECEIVING ANTHRACYCLIN AT KAUH; A RETROSPECTIVE STUDY تسمم الكبد لدى المرضي المصابين بالسرطان لسبب علاجهم بالدواء انثراساكلين بمستشفى جامعة الملك عبد العزيز |
|
Subject |
: |
Faculty of Applied Medical Sciences |
|
Document Language |
: |
Arabic |
|
Abstract |
: |
Background: Liver is a major organ that regulates the metabolism of toxins in the blood. The liver can affect the chemotherapy level in the blood in two different ways; 1- deactivation (the chemotherapy is metabolized to inactive molecule), 2- Excretion in the bile. Hepatocyte injury is a known complication in patients receiving chemotherapy. It ranges from mild elevation in liver enzymes to full picture of fulminant liver failure. The pathology includes hepatocellular injury, inflammation, or cholestasis. Anthracyclines is a common group of chemotherapeutics that are used in multiple protocols in treating cancer patients. All patients who received these medications are needed to monitor their liver functions closely. Early detection of these toxicities is very important to avoid further damage to hepatocytes. These toxicities have been reported in multiple trials that involved patients from North America and Europe. It is known that liver metabolism has some phenotypical differences. Aim: The aim of this retrospective study is to assess if we have any different profile of liver toxicity in cancer patients upon receiving first dose receiving Anthracyclines at King Abdulaziz University Hospital (KAUH). Method: This study was performed on 50 cancer patients who received anthracyclines at the department of Day Care Unit (DCU), KAUH, Jeddah between 2012 to 2017. The participants were selected based on predetermined inclusion criteria. The inclusion criteria were receiving anthracyclines chemotherapy (first dose) and the availability of patients' data before and after administration of anthracyclines. Sample collection procedures followed were in accordance to the local ethical guidelines. Patients date that obtained were; (age, gender, disease, therapeutic agent, administration date, results of liver function tests aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin (T.Bil) before and after administration of anthracyclines). Results: Our results conveyed that the ALT and T.Bil were the only parameters provided statistical significance difference. Their p-values were 0.001 and 0.012 respectively. AST results provided a border line significance difference with a p-value of 0.07. ALP results showed no significance difference with p-value 0.405. Additionally, because of the availability of TP, ALB and GGT results, their p-values were calculated. Both TP and ALB results revealed no significance difference with p-values of 0.132 and 0.131. Interestingly, GGT results displayed a significance difference with a p-value of 0.012. Conclusion: Although our results suggest that ALT, AST and GGT are elevated upon receiving the first dose of anthracyclines, their elevation doesn’t indicate hepatotoxicity. Thus, we failed to reject the null hypothesis and conclude that the liver function tests (ALT, AST, ALP and T.Bil) are not increased after receiving the first dose of anthracyclines in cancer patients. |
|
Supervisor |
: |
Dr. Adel Ghalzar Ahmed Chowdhury |
|
Thesis Type |
: |
Master Thesis |
|
Publishing Year |
: |
1439 AH
2017 AD |
|
Added Date |
: |
Wednesday, December 20, 2017 |
|
Researchers
| عبد الجواد عبدالشكور خان | Khan, Abdul Jawad Abdul Shakur | Researcher | Master | |
|
Back To Researches Page
|